Drug Trial Radar · NCT06922305
Relative Bioavailability Study of HR19042 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Dec 27, 2023
Primary completion
Jan 25, 2024
Study completion Jan 25, 2024
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, open-label, three-period, dual Latin square crossover study. Primary Objective: 1. To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release capsules (Tarpeyo®) and budesonide enteric-coated capsules (Budenofalk®). Secondary Objective 2. To assess safety following administration.
Conditions
- Primary IgA Nephropathy; Autoimmune Hepatitis
Interventions
HR19042 Capsule, Tarpeyo®, Budenofalk®Drug
In each period under fasting conditions, subjects received oral administration of either HR19042 Capsule 16 mg, Tarpeyo® 16 mg, or Budenofalk® 15 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax: Maximum plasma concentration. Blood samples will be collected.Time frame: From Day 1 up to Day 8
- AUC0-t: Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration. Blood samples will be collected.Time frame: From Day 1 up to Day 8
- AUC0-∞: Area under the plasma concentration-time curve from time 0 to infinity. Blood samples will be collected.Time frame: From Day 1 up to Day 8
- Tmax: Observed time to reach Cmax. Blood samples will be collected.Time frame: From Day 1 up to Day 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.